Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Corona Remedies IPO
Price Band
₹1008.0–1062.0
Issue Size
₹655.37 Cr
Lot Size
14 shares
Min Investment
₹14,868
GMP
+₹342.5 (32.25%)
Issue Price
₹1062.0
Subject to Sauda
₹3600
Paid only if allotted
Corona Remedies IPO AI Summary
- Corona Remedies IPO is listed on BSE, NSE in the Pharmaceuticals sector.
- Price band: ₹1008.0–₹1062.0 per share, lot size 14 shares (min. investment ₹14,868).
- Subscription window: 08 Dec–10 Dec 2025, listing on 15 Dec 2025.
- Current GMP is +₹342.5 (32.25%), an estimated listing price of ₹1405 — unofficial and can change daily.
Corona Remedies Limited is a growing pharmaceutical company with a diverse product portfolio and a strong marketing network. The upcoming IPO is priced at ₹1062.0, with a potential for listing gains indicated by a GMP of ₹342.5.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Corona Remedies IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 10 Dec 2025 — not a current signal.
Reviewers are split — see individual calls below.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Corona Remedies IPO Grey Market Premium (GMP) Today
GMP
+₹342.5
GMP %
+32.25%
Est. Listing
₹1404.5
Updated: 25 Jul 2026 14:15
About the Company
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas. As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory). The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas. The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum. Competitive Strength: Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market. Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas. Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market. Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products. Qualified, experienced and entrepreneurial management team supported by marquee investors.
Company Financials (₹ Cr)
As of 2025-06-30
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| NET Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
Key Ratios
EPS
₹24.43
NAV
₹99.14
ROE
27.50%
ROCE
41.32%
RoNW
24.65%
P/B Value
10.71
P/E Ratio
43.47
Market Cap
₹6495.20 Cr
PAT Margin
12.49%
Debt/Equity
0.10
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Ltd. | 224.28 | 25.18% | 65.91 | 56.47 | 56.47 |
| Sanofi India Ltd. | 373.68 | 48.05% | 24.47 | 179.46 | 179.46 |
| Pfizer Ltd. | 921.88 | 18.2% | 29.63 | 167.79 | 167.79 |
| Mankind Pharma Limited | 352.51 | 13.89% | 45.77 | 49.28 | 49.2 |
| J.b.chemicals & Pharmaceuticals Ltd. | 220.88 | 19.21% | 42.6 | 42.45 | 41.56 |
| Glaxosmithkline Pharmaceuticals Ltd. | 115.19 | 47.54% | 46.87 | 54.76 | 54.76 |
| Eris Lifesciences Ltd | 209.73 | 12.21% | 61.81 | 25.85 | 25.81 |
| Alkem Laboratories Ltd | 1002.37 | 18.07% | 31.39 | 181.11 | 181.11 |
| Abbott India Ltd. | 1992.14 | 33.41% | 45.17 | 665.62 | 665.62 |
| Corona Remidies Limited This IPO | 99.14 | 24.65% | — | 24.43 | 24.43 |
Promoters
Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Ankur Kirtikumar Mehta
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹891.10 Cr in the year ending 31 Mar 2023, rising to ₹1,020.93 Cr by 31 Mar 2024, and further increasing to ₹1,202.35 Cr by 31 Mar 2025. However, for the period ending 30 Jun 2025, total income dropped to ₹348.56 Cr, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹84.93 Cr in the year ending 31 Mar 2023, increasing to ₹90.50 Cr by 31 Mar 2024, and then to ₹149.43 Cr by 31 Mar 2025. For the period ending 30 Jun 2025, profit after tax was ₹46.20 Cr, though this is a 9-month figure, not a full year, so isn't directly comparable.
Valuation
At the issue price of ₹1062.0, Corona Remedies has an implied P/E ratio of approximately 43.47, while peers are trading at a P/E range of 24.47 to 65.91.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the expected listing price of an IPO based on unofficial trading before its official listing. A positive GMP suggests that the IPO is likely to list at a higher price than its issue price, while a negative GMP indicates the opposite.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their risk tolerance and investment goals, considering factors such as the company's growth potential and market position.
Who May Want to Wait
Investors who prefer stable and predictable returns may want to avoid IPOs like this, which can be subject to market fluctuations and may not provide immediate returns.
IPO Timeline, Explained
The IPO process involves several key dates: the opening date for subscription is on 8th December 2025, closing on 10th December 2025, with allotments expected by 11th December 2025 and listing on 15th December 2025.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make if the stock price rises on the first day of trading. However, such gains are not guaranteed and can be influenced by market conditions, investor sentiment, and overall demand for the stock.
This evaluation is generated from Corona Remedies's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Corona Remedies IPO GMP today?
Corona Remedies IPO GMP today is +₹342.5 (32.25%), indicating an estimated listing price of ₹1405. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Corona Remedies IPO?
The price band of Corona Remedies IPO is ₹1008.0–₹1062.0 per share.
When does Corona Remedies IPO open and close?
Corona Remedies IPO opens on 08 December 2025 and closes on 10 December 2025.
When does Corona Remedies IPO list on the stock exchange?
Corona Remedies IPO listed on 15 December 2025 at ₹1404.5.
What is the lot size for Corona Remedies IPO?
The lot size for Corona Remedies IPO is 14 shares, requiring a minimum investment of ₹14,868.
What is the price band for the Corona Remedies IPO?
The price band for the Corona Remedies IPO is ₹1008.0 to ₹1062.0.
What is the minimum investment required?
The minimum investment required is ₹14,868.0.
What is the lot size for this IPO?
The lot size for the Corona Remedies IPO is 14 shares.
When does the IPO open and close?
The IPO opens on 8th December 2025 and closes on 10th December 2025.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing price of the IPO based on unofficial trading.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
08 Dec 2025
Close
10 Dec 2025
Allotment
11 Dec 2025
Listing
15 Dec 2025
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Corona Remedies?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.